2:34
What’s next for rare myelomas?
Elena Zamagnia
3:55
Overview of the SIRIUS clinical trial in the treatment of multiple myeloma
Maria-Victoria Mateos
4:12
How can MRD and disease be assessed in routine practice?
Joan Bladé
1:36
Features of high-risk multiple myeloma and how to treat it
Keith Stewart
2:30
Biomarkers of cardiotoxicity in multiple myeloma
Ola Landgren
